<SEC-DOCUMENT>0001178913-23-002778.txt : 20230809
<SEC-HEADER>0001178913-23-002778.hdr.sgml : 20230809
<ACCEPTANCE-DATETIME>20230809090007
ACCESSION NUMBER:		0001178913-23-002778
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230809
FILED AS OF DATE:		20230809
DATE AS OF CHANGE:		20230809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		231153565

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2330138.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;"> <font style="font-size: 14pt;"><br>
          </font></font></div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-size: 14pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">UNITED STATES&#160;</font>&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C.&#160;20549</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">For the month of August 2023<font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font>Commission File No.:001-35773</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Address of principal executive offices)</div>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover Form
        20-F or Form 40-F.<br>
      </div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: #000000;"> <br>
        </div>
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746;&#160; Form 40-F&#160;&#9744;</div>
      <div style="text-indent: 14.2pt; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: #000000;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by
        Regulation S-T Rule 101(b)(1): ____&#160;</div>
      <div style="text-indent: 28.35pt; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: #000000;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by
        Regulation S-T Rule 101(b)(7): ____</div>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; line-height: 1.25; color: #000000;">At the Annual General Meeting of Shareholders of Redhill Biopharma Ltd. (the &#8220;Company&#8221;) held on August 9, 2023, the
        following proposed resolutions were approved by the shareholders:</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0d3cc0b33d5d4c24b769b331e59727a8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To appoint Kesselman &amp; Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International
                Limited, as the Company&#8217;s auditors for the year 2023 and for an additional period until the next Annual General Meeting;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2a2dcb8a45a34d55863ba4f52da81663" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the re-election of Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the board of directors of the Company (the &#8220;Board of
                Directors&#8221;) for an additional three-year term until the annual general meeting to be held in 2026; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z56189f6c10fe4fcfa737ffb45061f754" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the engagement by the Company of Mr. Dror Ben-Asher to serve as the Company's Chairman of the Board of Directors and the
                Company's Chief Executive Officer.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; color: #000000;">The following proposed resolutions were not approved by the shareholders:&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="zfe03ad42f997426b9833f1c03e8ecea1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the grant of restricted share units (&#8220;RSUs&#8221;) each with respect to one American Depository Share (each representing 400
                ordinary shares, par value NIS 0.01 each) (&#8220;ADSs&#8221;) to Mr. Dror Ben-Asher, the Company&#8217;s Chief Executive Officer and Director;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z02d290f3672348509003129135b43eaf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company&#8217;s Chief Commercial Officer and Director;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3753c93bd33d408f9d378b267687b33a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve a grant of RSUs of the Company to the non-executive directors of the Company; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zeed6c4ccb9bd46e6bd87a662c6be7e34" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1.04%; vertical-align: top;">&#160;</td>
            <td style="width: 2.46%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4.</div>
            </td>
            <td style="width: 96.5%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve an increase in the Company&#8217;s authorized share capital.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; color: #000000;">This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with
          the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24,
          2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845) and on June 29, 2023 (File No. 333-273001) and its
          Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on July 29, 2021 (File No. 333-258259) and on August 4, 2023 (File No. 333-273709).</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">SIGNATURES</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be
        signed on its behalf by the undersigned, thereunto duly authorized.&#160;</div>
      <div style="text-align: justify; margin-left: 220.65pt; line-height: 1.25; color: #000000;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zad2d0f970232416b953ec194e9ff6223" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">REDHILL BIOPHARMA LTD.</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(the &#8220;Registrant&#8221;)</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date: August 9, 2023</div>
            </td>
            <td style="width: 3%; vertical-align: middle;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By:</div>
            </td>
            <td style="width: 35%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;/s/ Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Dror Ben-Asher&#160;</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.66%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chief Executive Officer</div>
            </td>
            <td style="width: 12%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25; color: #000000;"> <br>
        </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">
        <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font> <br>
          </div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
